Gottschalk

InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial

Retrieved on: 
Friday, November 3, 2023
FDA, Stem Cells, Pharmaceutical, Surgery, Physical Therapy, Managed Care, General Health, Hospitals, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Patient, Insurance, VAS, RT, Syndrome, Ludwig Maximilian University of Munich, Literature, Policy, Treatment, Visual analogue scale, Khaneqah Bala va Pain, Injection, OA, Pain, CSI, Osteoarthritis, KOOS, Evidence-based medicine, Cell, Clinical trial, Guideline, Knee, Emory University, MILES, Total, Knee pain, Gottschalk, Pharmaceutical industry, Medical imaging, InGeneron

InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).

Key Points: 
  • InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).
  • Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
  • At InGeneron, we are dedicated to evidence-based medicine and deeply value our partnerships with respected institutions like Emory University.
  • Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.

Foghorn Therapeutics Announces Chief Medical Officer Succession

Retrieved on: 
Tuesday, August 8, 2023
GSK, Chromatin, Cancer, MD Anderson Cancer Center, Gene expression, Novartis, Patient, Gottschalk, CTL019, Biology, Leukemia, FDA, Pharmaceutical industry, Foghorn

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief Medical Officer, on September 11, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief Medical Officer, on September 11, 2023.
  • Foghorn’s current Chief Medical Officer, Sam Agresta, M.D., will simultaneously retire from the company on September 11, 2023, and will provide consulting services through early January 2024.
  • “I want to thank Sam for his leadership and many contributions to Foghorn over the past four years.
  • He joined the company at a critical time and built our clinical team which advanced our first programs to the clinic,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.

SVB Fallout: VC & Tech Startup Founders at Risk, Presented by JOTO PR Disruptors

Retrieved on: 
Monday, April 10, 2023
Insurance, Risk, AskMe, Failure, General counsel, TechCrunch, Public opinion, Lloyd, Silicon Valley Bank, Risk management, Web conferencing, Lloyd's of London, Vinod Khosla, Silicon, Trust, Investment, SVB, AMA, VCS, Growth, Sun Microsystems, VC, Weapons in Star Trek, Safety, Cryptocurrency, Renewable energy, Video game, Gottschalk

JoTo PR Disruptors is presenting a free webinar masterclass on Thursday, April 27, 2023, 12:00 PM EST, SVB Fallout: VC & Tech Startup Founders at Risk , that provides an opportunity to glean insight from Gottschalk into risk management, trust and safety, compliance & regulatory and legal strategy for marketplaces and digital platforms.

Key Points: 
  • JoTo PR Disruptors is presenting a free webinar masterclass on Thursday, April 27, 2023, 12:00 PM EST, SVB Fallout: VC & Tech Startup Founders at Risk , that provides an opportunity to glean insight from Gottschalk into risk management, trust and safety, compliance & regulatory and legal strategy for marketplaces and digital platforms.
  • Identifying and mitigating risk determines success vs failure especially for innovative and disruptive marketplaces and digital platforms.
  • As an Anti-PR® Agency, JoTo PR Disruptors employ the best practices to succeed in business today.
  • Goal: Actionable steps you can use to accelerate your growth, which is what JOTO PR Disruptors is all about.

The Latin GRAMMY Cultural Foundation® Announces Winners of Its Research and Preservation Grant Program

Retrieved on: 
Thursday, February 16, 2023
Research, Entertainment, Hispanic, Philanthropy, Music, University, Consumer, Foundation, Science, Education, Canción, Life, Collection, Catholic University of America, Human, Attention, City University, Dominican Republic, Distribution, LAMC, CUNY Dominican Studies Institute, New Music USA, Pleasure, Gottschalk, Rescate Wildlife Rescue Center, Poetry, Culture, Education for librarianship, Catholic higher education, Movement, Nuevo, Student, Mercedes Sosa, City, The, Discography, Pan-Americanism, National University of Cuyo, Louisiana State University, Faculty, Father, Quarter-inch cartridge, Book, Grant (money), Creative industries, Latin

The Latin GRAMMY Cultural Foundation® announced the winners of its Research and Preservation Grant program.

Key Points: 
  • The Latin GRAMMY Cultural Foundation® announced the winners of its Research and Preservation Grant program.
  • “For the eighth consecutive year, we have the pleasure and privilege of awarding Research and Preservation Grants to deserving Latin music creators,” said Raquel “Rocky” Egusquiza, Executive Director of the Latin GRAMMY Cultural Foundation.
  • In 2021, a Preservation Grant from the Latin GRAMMY Cultural Foundation supported the launch of Phase 1 of the LAMC’s archival and preservation project.
  • Since its inception in 2015, the program has awarded more than $175,000 in grants to support projects, one of which received a Latin GRAMMY® and GRAMMY® Award.

Helmut Gottschalk has decided to be no longer available as Chairman of the Supervisory Board. Dr. Jens Weidman to be nominated for election as successor

Retrieved on: 
Sunday, November 27, 2022
Annual, Committee, Gottschalk, Commerzbank, Supervisory board, Timeline of the Jimmy Carter presidency (1980–January 1981), Risk management, MAR, Property management

Helmut Gottschalk has decided to be no longer available as Chairman of the Supervisory Board.

Key Points: 
  • Helmut Gottschalk has decided to be no longer available as Chairman of the Supervisory Board.
  • Dr. Jens Weidman to be nominated for election as successor
    Dissemination of a Regulatory Announcement that contains inside information in accordance with the Market Abuse Regulation (MAR), transmitted by EQS Group.
  • He has furthermore proposed Dr. Weidmann as new member of the Supervisory Board, who will also be available as Chairman of the Supervisory Board if he is elected.
  • It is also intended that he will subsequently be elected the successor of Helmut Gottschalk as Chairman.

American Vanguard Announces Voting Results of 2022 Annual Meeting of Stockholders

Retrieved on: 
Monday, June 6, 2022
Professional Services, Chemicals, Plastics, Other Professional Services, Manufacturing, Agriculture, Natural Resources, Finance, Optimism, Company, American Vanguard Corporation, Gottschalk, BDO, Crop protection, Annual general meeting, Standard, Rosenbloom, Health, NYSE, Weather, History, Russell, LLP, Person, AVD, Security (finance), Holding company, Oil, Cruiser

American Vanguard Corp. (NYSE:AVD) announced voting results arising from the Annual Meeting of Stockholders held on June 1, 2022.

Key Points: 
  • American Vanguard Corp. (NYSE:AVD) announced voting results arising from the Annual Meeting of Stockholders held on June 1, 2022.
  • These persons will serve as directors until the next annual meeting or until their successors are duly elected and qualified.
  • Chairman and CEO Eric W. Wintemute commented, We thank our shareholders for voting at the annual meeting.
  • American Vanguard is included on the Russell 2000 and Russell 3000 Indexes and the Standard & Poors Small Cap 600 Index.

Both Leading Proxy Advisory Firms – ISS and Glass Lewis – Recommend American Vanguard Stockholders Vote FOR All Three of Cruiser Capital’s Nominees on the BLUE Proxy Card

Retrieved on: 
Friday, May 20, 2022
Professional Services, Finance, Company, EBITDA, U.S. Securities and Exchange Commission, Rosenbloom, Investment, Policy, Income, BLUE, Nature, Glass, TSR, Gottschalk, Metamorphosis, Floor, Info, American Vanguard Corporation, Industry, Retirement, Time, Participation, Nomination, Board, Cruiser, Communication, Proxy, Elevate, AVD, ALL, Security (finance), Person, Glass Lewis, SEC, LLC, Growth, ISS, NYSE, Holding company, Risk management, Management, Recycling, Marketing, Weapon, American, Shareholder

Importantly, AVD share price increased 4.3 percent on April 19, 2022, outperforming peers by 4.4 percentage points.

Key Points: 
  • Importantly, AVD share price increased 4.3 percent on April 19, 2022, outperforming peers by 4.4 percentage points.
  • Rose of Cruiser Capital Advisors stated: We appreciate that both ISS and Glass Lewis recognize independent voices are needed on the American Vanguard Board.
  • Cruiser encourages stockholders to follow the recommendations of both Glass Lewis and ISS and vote today on the BLUE proxy card to help Elevate AVD.
  • Stockholders are urged to read the definitive proxy statement and BLUE proxy card, because they contain important information about the Nominees, the Company and related matters.

Glass Lewis Recommends American Vanguard Stockholders Vote FOR All Three of Cruiser Capital’s Nominees on the BLUE Proxy Card

Retrieved on: 
Thursday, May 19, 2022
Banking, Professional Services, Finance, Risk, Company, EBITDA, U.S. Securities and Exchange Commission, Rosenbloom, Basset, Disclosure, Investment, BLUE, Dissident, Review, Nature, Glass, TSR, Gottschalk, American Vanguard Corporation, Metamorphosis, Info, CCA, Industry, Participation, Nomination, Cruiser, Communication, Proxy, AVD, ALL, Security (finance), Person, Glass Lewis, Acquisition, SEC, LLC, Growth, NYSE, Holding company, Risk management, Management, American, Shareholder

Regarding the individual Cruiser nominees, Glass Lewis notes, Mr. Basset appears to have an extensive operational background in the chemicals industryMr.

Key Points: 
  • Regarding the individual Cruiser nominees, Glass Lewis notes, Mr. Basset appears to have an extensive operational background in the chemicals industryMr.
  • Cruiser Capital stated: Were very pleased Glass Lewis shares our conclusion that change is needed in the American Vanguard boardroom.
  • Cruiser encourages stockholders to follow Glass Lewiss recommendation and vote today on the BLUE proxy card to help elevate AVD.
  • Stockholders are urged to read the definitive proxy statement and BLUE proxy card, because they contain important information about the Nominees, the Company and related matters.

American Vanguard Files Definitive Proxy Materials and Sends Letter to Stockholders

Retrieved on: 
Monday, May 2, 2022
Consulting, Banking, Professional Services, Finance, Board of directors, DO, Central, American Vanguard Corporation, Ultimus, AVD, Technology, Annual general meeting, Rose, Agriculture, Carbon, Woman, Company, NYSE, Soil, Letter, Industry, Food, ESG, Crop protection, Bring Your Board!!, EBITDA, U.S. Securities and Exchange Commission, ALL, Telephone, Time, Russell, Gottschalk, IP, Growth, Internet, Board, COVID-19, Proxy, Health, Science and technology in Asia, Special-purpose acquisition company, Mail, Holding company, Renewable energy, Financial services, Security (finance), Management, Sales, Shareholder, American, Cruiser, Director

The Board of Directors of American Vanguard urges stockholders to sign and return the Companys WHITE proxy card and disregard any proxy card received from Cruiser.

Key Points: 
  • The Board of Directors of American Vanguard urges stockholders to sign and return the Companys WHITE proxy card and disregard any proxy card received from Cruiser.
  • The letter sent to stockholders highlights the following points:
    The American Vanguard Board is committed to serving the interests of ALL stockholders and to continue driving long-term value creation.
  • There is significant embedded value in our Company, including in our SIMPAS platform and growing Green Solutions portfolio, which offers clear upside to all American Vanguard stockholders.
  • Your Board and management understand our business and have put in place the building blocks to drive long-term value for all American Vanguard stockholders.

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

Retrieved on: 
Thursday, March 10, 2022
Nasdaq, Mum, Clinical trial, Â, Choroid, Cost sharing, Chromatin, Ciliary body, BAF, Company, Ligament, Research, U.S. Securities and Exchange Commission, Gottschalk, BRD9, Iris, Cell, Sarcoma, AML, Cancer, 23rd Street station (IND Eighth Avenue Line), Mutation, Economics, Synovial sarcoma, MDS, Adult, Bone marrow, Acute leukemia, ARID1A, GLOBE, BRM, Gene expression, Acute myeloid leukemia, Security (finance), ATPase, Blood, Myelodysplastic syndrome, BRG1, Therapy, Lilly, Neoplasm, Program, ARID1B, Forward-looking statement, NSCLC, Protein, Fine chemical, Cryptocurrency, Pharmaceutical industry, Vaccine, Dietary supplement, Foghorn

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update including the Company’s 2021 key achievements and 2022 strategic priorities in conjunction with its 10-K filing for the year ended December 31, 2021. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • In January 2022, Foghorn added Dannette Daniels as our Vice President, Protein Degrader Platform, continuing our investment in and expansion of our protein degrader capabilities.
  • In December 2021, Foghorn and Lilly announced a strategic collaboration for novel oncology targets using Foghorns proprietary Gene Traffic Control Platform.
  • In December 2021, Foghorn and Loxo Oncology at Lilly entered into a strategic collaboration for novel oncology targets.
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.